Skip to content
Screener

Eton Pharmaceuticals, Inc. ETON Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

HRO
HarrowHROW
$944K+20.7%
XER
Xeris Biopharma Holdings, Inc.XERS
$6.31M+2.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$626K+19.2%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$636K+39.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$57.3M+25.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.32M-30.7%

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K—
Free cash flow$7.3M+251%

Valuation

See full
Market cap$1.22B+167%
Enterprise value$1.23B+167%
P/S14.1×+6.2×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%—
Net margin-9.5%-2.7pp
FCF margin17.1%—

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity1×-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Eton Pharmaceuticals, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001437749-26-017064
AssetsClassificationMarch 31, 2026December 31, 2025
Operating lease right-of-use assetsOperating lease right-of-use assets, net$301$310
Total leased assets$301$310
Liabilities
Operating lease liabilities, currentAccrued liabilities$75$65
Operating lease liabilities, noncurrentOperating lease liabilities, net of current portion440460
Total operating lease liabilities$515$525

Document

FAQ

What is Eton Pharmaceuticals, Inc.'s operating lease liabilities (current)?
Eton Pharmaceuticals, Inc. (ETON) reported operating lease liabilities (current) of $75K in Q1 2026.
How has Eton Pharmaceuticals, Inc.'s operating lease liabilities (current) changed year-over-year?
Eton Pharmaceuticals, Inc.'s operating lease liabilities (current) decreased by 2.6% year-over-year, from $77K to $75K.
What is the long-term trend for Eton Pharmaceuticals, Inc.'s operating lease liabilities (current)?
Over 4 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s operating lease liabilities (current) has grown at a -24.0% compound annual growth rate (CAGR), from $195K to $65K.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Eton Pharmaceuticals, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude